Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
Werte in diesem Artikel
Conference Call and Webcast to Follow
WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.
Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Thursday, July 31, 2025, beginning at 11:00 AM ET and will be accessible until Thursday, August 7, 2025, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 9430387.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2025-financial-results-on-july-31-2025-302512437.html
SOURCE Vanda Pharmaceuticals Inc.
Übrigens: Vanda Pharmaceuticals und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Vanda Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vanda Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Vanda Pharmaceuticals IncShs
Analysen zu Vanda Pharmaceuticals IncShs
Datum | Rating | Analyst | |
---|---|---|---|
11.12.2018 | Vanda Pharmaceuticals Perform | Oppenheimer & Co. Inc. | |
04.12.2018 | Vanda Pharmaceuticals Overweight | Cantor Fitzgerald | |
21.09.2018 | Vanda Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
19.01.2018 | Vanda Pharmaceuticals Buy | Seaport Global Securities | |
26.05.2017 | Vanda Pharmaceuticals Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
04.12.2018 | Vanda Pharmaceuticals Overweight | Cantor Fitzgerald | |
21.09.2018 | Vanda Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
19.01.2018 | Vanda Pharmaceuticals Buy | Seaport Global Securities | |
26.05.2017 | Vanda Pharmaceuticals Buy | H.C. Wainwright & Co. | |
09.11.2016 | Vanda Pharmaceuticals Buy | Aegis Capital |
Datum | Rating | Analyst | |
---|---|---|---|
11.12.2018 | Vanda Pharmaceuticals Perform | Oppenheimer & Co. Inc. | |
30.07.2008 | Vanda Pharmaceuticals Downgrade | Banc of America Securities LLC | |
29.07.2008 | Vanda Pharmaceuticals Downgrade | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vanda Pharmaceuticals IncShs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen